Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
East Asian Arch Psychiatry ; 34(1): 3-8, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38955777

ABSTRACT

BACKGROUND: During the COVID-19 pandemic, social-distancing and confinement measures were implemented. These may affect the mental health of patients with mental disorders such as schizophrenia. This study examined the clinical course of patients with schizophrenia at a public hospital in Morocco during the COVID-19 pandemic. METHODS: This longitudinal observational study was conducted across three periods in 15 months: 1 April 2020 (start of strict home confinement) to 30 June 2020 (T1), 1 July 2020 to 31 January 2021 (corresponding to the Delta wave) [T2], and 1 February 2021 to 30 June 2021 (corresponding to the Omicron wave) [T3]. Patients aged 18 to 65 years with a diagnosis of schizophrenia or schizoaffective disorder (based on DSM 5) made before the pandemic who presented to the Faculty of Medicine and Pharmacy of Rabat were invited to participate. Psychotic symptomatology was evaluated using the Positive and Negative Syndrome Scale (PANSS). Severity and improvement of mental disorder were evaluated using the Clinical Global Impression (CGI)-Severity and -Improvement subscales. Depressive symptoms were assessed using the Calgary Depression Scale (CDS). Adherence to treatments was assessed using the Medication Adherence Rating Scale (MARS). All assessments were made by psychiatrists or residents face-to-face (for T1) or via telephone (for T2 and T3). RESULTS: Of 146 patients recruited, 83 men and 19 women (mean age, 39 years) completed all three assessments. The CGI-Severity score was higher at T2 than T1 and T3 (3.24 vs 3.04 vs 3.08, p = 0.041), and the MARS score was higher at T1 and T2 than T3 (6.80 vs 6.83 vs 6.35, p = 0.033). Patient age was negatively correlated with CDS scores for depressive symptoms at T1 (Spearman's rho = -0.239, p = 0.016) and at T2 (Spearman's rho = -0.231, p = 0.019). The MARS score for adherence was higher in female than male patients at T1 (p = 0.809), T2 (p = 0.353), and T3 (p = 0.004). Daily tobacco consumption was associated with the PANSS total score at T3 (p = 0.005), the CGI-Severity score at T3 (p = 0.021), and the MARS score at T3 (p = 0.002). Patients with a history of attempted suicide had higher CDS scores than those without such a history at T1 (p = 0.015) and T3 (p = 0.018) but not at T2 (p = 0.346). CONCLUSION: Home confinement during the COVID-19 pandemic had limited negative impact on the mental health of patients with schizophrenia in Morocco.


Subject(s)
COVID-19 , Schizophrenia , Humans , COVID-19/epidemiology , COVID-19/psychology , Morocco , Male , Female , Adult , Longitudinal Studies , Middle Aged , Schizophrenia/epidemiology , Young Adult , Adolescent , Psychotic Disorders/epidemiology , Psychotic Disorders/psychology , Antipsychotic Agents/therapeutic use , Aged , Medication Adherence/statistics & numerical data , Medication Adherence/psychology , Psychiatric Status Rating Scales , Depression/epidemiology , Depression/psychology , SARS-CoV-2
2.
Nat Commun ; 13(1): 2485, 2022 05 18.
Article in English | MEDLINE | ID: mdl-35585047

ABSTRACT

The utility of cancer whole genome and transcriptome sequencing (cWGTS) in oncology is increasingly recognized. However, implementation of cWGTS is challenged by the need to deliver results within clinically relevant timeframes, concerns about assay sensitivity, reporting and prioritization of findings. In a prospective research study we develop a workflow that reports comprehensive cWGTS results in 9 days. Comparison of cWGTS to diagnostic panel assays demonstrates the potential of cWGTS to capture all clinically reported mutations with comparable sensitivity in a single workflow. Benchmarking identifies a minimum of 80× as optimal depth for clinical WGS sequencing. Integration of germline, somatic DNA and RNA-seq data enable data-driven variant prioritization and reporting, with oncogenic findings reported in 54% more patients than standard of care. These results establish key technical considerations for the implementation of cWGTS as an integrated test in clinical oncology.


Subject(s)
Gene Expression Profiling , Neoplasms , Child , Feasibility Studies , Gene Expression Profiling/methods , High-Throughput Nucleotide Sequencing/methods , Humans , Neoplasms/diagnosis , Neoplasms/genetics , Prospective Studies , Transcriptome/genetics , Whole Genome Sequencing/methods , Young Adult
3.
Arch Inst Pasteur Tunis ; 91(1-4): 33-41, 2014.
Article in French | MEDLINE | ID: mdl-26402968

ABSTRACT

Toxins from animal venoms are small peptide molecules able to interact with a wide range of specific cellular targets in order to modulate their activity, which enables them to act in many physiological and pathological processes. Recently, structuralandpharmacologicalstudieshaveshown the involvement of these biological agents in the pathogenesis of many diseases like diabetes, cancer paralysis, autoimmune diseases or neurological disorders. Nevertheless, the only punfication from scorpion venoms of theses peptides still doesn't offer sufficient quantities to allow conducting the pharmacological and structure-function studies. The solid phases peptide synthesis (SPPS) is a methodology that allows us to produce non-limited quantities of structural analogsfrom these peptides-toxins in. In this paper; we will try to highlight the importance of this methodology, and peptide engineering in general, in obtaining peptides of interest. We are also going to elucidate the problems encountered during the chemical synthesis of some betides and explain how to overcome them.


Subject(s)
Scorpion Venoms/chemical synthesis , Solid-Phase Synthesis Techniques/methods , Animals , Peptides, Cyclic/chemical synthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...